Can-Fite BioPharma (CANF) C-level Sitdown summary

Clinical development pipeline

• Two drugs in clinical development: Piclidenoson and Namodenoson, targeting psoriasis, Lowe syndrome, pet osteoarthritis, advanced liver cancer, and pancreatic cancer.

• Pivotal phase III studies for psoriasis and advanced liver cancer are underway, with regulatory agreements in place.

• Phase IIa trial for Namodenoson in pancreatic cancer has begun, enrolling 20 patients in the U.S. and Israel.

• Ongoing phase IIb study for NASH after successful phase IIa results; preclinical program for erectile dysfunction is also in progress.

Market opportunities and partnerships

• Psoriasis drug market projected to reach $32 billion by 2028; pet osteoarthritis market expected to grow to $6.3 billion by 2030.

• Partnership with VetBioBank for Piclidenoson in pet osteoarthritis could capture up to 6% of the market, with projected worldwide sales of $445 million by 2034.

• Agreement includes 50% royalties on worldwide sales, with upfront royalty sales projected at $325 million over 10 years.

Differentiation and financial position

• Namodenoson received Orphan Drug designation for pancreatic cancer, addressing a market with limited effective treatments and low survival rates.

• Both Piclidenoson and Namodenoson have demonstrated safety and efficacy in late-stage trials.

• Over $20 million received from licensing deals, with potential for an additional $130 million plus royalties.

• Intellectual property portfolio includes 15 patent families covering multiple indications.

• Financial resources are sufficient to support ongoing clinical development programs.